Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Description

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Conditions

Colorectal Cancer, Sarcopenia

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will examine the association between low muscle mass (myopenia) at diagnosis and chemotherapy toxicity in older adults with newly diagnosed advanced colorectal cancer.

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

Condition
Colorectal Cancer
Intervention / Treatment

-

Contacts and Locations

Frankford

Beebe South Coastal Health Campus, Frankford, Delaware, United States, 19945

Newark

Helen F Graham Cancer Center, Newark, Delaware, United States, 19713

Newark

Medical Oncology Hematology Consultants PA, Newark, Delaware, United States, 19713

Rehoboth Beach

Beebe Health Campus, Rehoboth Beach, Delaware, United States, 19971

Washington

MedStar Georgetown University Hospital, Washington, District of Columbia, United States, 20007

Bloomington

Illinois CancerCare-Bloomington, Bloomington, Illinois, United States, 61704

Canton

Illinois CancerCare-Canton, Canton, Illinois, United States, 61520

Chicago

John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States, 60612

Danville

Carle at The Riverfront, Danville, Illinois, United States, 61832

Decatur

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States, 62526

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Newly diagnosed metastatic CRC or newly recognized metastatic recurrence of CRC \>= to 3 months (12 weeks) from completion of treatment of non-metastatic CRC.
  • * Planning to or recently started to undergo undergo immunotherapy and/or 5-FU based chemotherapy as a first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan +/- immunotherapy. Capecitabine is also acceptable.
  • * Estimated life expectancy \>= 6 months.
  • * Patients must be able to comprehend English or Spanish (for questionnaire completion).
  • * Ability to understand and the willingness to sign a written informed consent document.
  • * Patient eligibility is not dependent on BMI or weight. Patients with a significant (+- \> 10%) body weight change in the previous 12 months are eligible for this study.
  • * Patients enrolled on hospice.
  • * Prior systemic chemotherapy for metastatic colorectal cancer (ok if adjuvant chemotherapy completed \>= 3 months (12 weeks) prior to this disease disease recurrence and treatment).
  • * Patients may not be receiving any other investigational agents.
  • * No untreated brain metastases. Patients with treated brain metastases are eligible.
  • * Patients on or planned to undergo radiation therapy in near future.

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Grant R Williams, MD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

2024-12-31